Purpose: The pharmacology, pharmacokinetics, clinical efficacy ... Pregabalin has demonstrated efficacy in the management of neuropathic pain associated with diabetic peripheral neuropathy ...

The efficacy of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy has been established in several controlled clinical trials. [17,18,19] These trials ...

QUTENZA ® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and ...

QUTENZA ® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN ...

Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...

ITDD helps effectively manage chronic pain and spasticity in some patients but requires adherence to best practices and a ...

has completed recruitment for the Phase III clinical trial AV001 ... 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S. label.

More information: Mikael Åkerlund et al, Genetic associations of neuropathic pain and sensory profile in a deeply phenotyped neuropathy cohort, Pain (2024). DOI: 10.1097/j.pain.0000000000003463 ...

has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA® (capsaicin) 8% topical system in post-surgical neuropathic ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...